# Regeneron's Billion-Dollar Catalyst Under Wall Street's Radar

> Regeneron's earnings reveal a hidden profit boost from Dupixent as Sanofi partnership shifts.
- Title: Regeneron's Billion-Dollar Catalyst Under Wall Street's Radar
- Summary: Regeneron's earnings reveal a hidden profit boost from Dupixent as Sanofi partnership shifts. Regeneron's third-quarter earnings show a $930 million profit…
- Keywords: regeneron, sanofi, dupixent, earnings, q3 2026, nasdaq:regn, sanofi partnership, biologics, Regeneron's, Billion-Dollar, Catalyst, Under
- Source: 24/7 Wall St. — https://247wallst.com/investing/2026/10/26/regenerons-billion-dollar-catalyst-flying-under-wall-streets-radar-ahead-of-oct-30-earnings
- Author: Rich Duprey
- Published: 2026-10-26T13:39:48+00:00
- Read time: 1 min
- Topics: regeneron, sanofi, dupixent, earnings, q3 2026, nasdaq:regn, sanofi partnership, biologics
## Regeneron Reports Q3 Earnings
Regeneron releases third-quarter results on Oct 30 with a key accounting change from Sanofi partnership.
## Dupixent Profit Drag Removed
Regeneron fully returns Sanofi development balance, cutting reported collaboration revenue by $930 million in 2025.
## Sanofi Partnership Shifts
Regeneron and Sanofi expand alliance worth up to $8 billion to settle prior litigation and add four long-acting antibodies.
## Analysts Expect EPS Jump
Analysts forecast Regeneron's Q3 2026 normalized EPS at $16.198, up 36.9% from prior-year actual.
## Eylea HD Sales Surge
U.S. Eylea HD sales hit $596 million last quarter, up 52%, passing legacy Eylea for the first time.
## Dupixent's True Earnings Power
This quarter reveals Dupixent's full earnings impact after Sanofi repayment removes profit drag.
## Key takeaway

Regeneron's third-quarter earnings show a $930 million profit increase from Sanofi partnership changes after Dupixent's sales surge.